Janus Living, Inc. (JAN) Stock Price & How to Invest

Janus Living, Inc. (NYSE: JAN) owns senior housing communities across the United States and, unusually for a healthcare REIT, takes the operating result of those communities rather than a fixed rent. Every property sits in a RIDEA structure, meaning Janus Living books resident fees and pays the operating costs, with third parties such as LCS, Sunrise Senior Living and Ciel Senior Living running the buildings under management contracts. The portfolio at June 30, 2026 was ~41 communities and ~11,420 units across ~13 states, weighted heavily toward Florida, which accounted for roughly ~51% of gross real estate assets, with Texas and Pennsylvania each near ~11%. A large slice of the portfolio is life plan communities, the entrance fee format where residents pay a substantial sum up front for the right to live on a campus that also offers assisted living and skilled care, which is why the balance sheet carries ~$699M of deferred revenue and another ~$227M of refundable entrance fees. Janus Living is externally managed by Healthpeak Investment Management, an indirect subsidiary of Healthpeak Properties (NYSE: DOC), and is headquartered in Denver.

The listing history is short and the growth has been abrupt. Shares priced at ~$20.00 in the March 2026 IPO, closed at ~$30.18 on August 10, and the company has since raised capital twice more, taking in roughly ~$690M net in June and about ~$447M net in an August offering of ~16.0M shares at ~$29.00. That money has gone straight into buying communities: roughly ~$1.8B of acquisitions year to date, at targeted stabilized cash NOI yields of ~7.5% to ~9.5%. The operating numbers underneath are strong. Second quarter revenue of ~$216M rose ~45% against the prior year, same-store adjusted NOI grew ~19.2% on ~8.4% revenue growth, average occupancy reached ~85.5%, and FFO as Adjusted per share climbed ~40% to ~$0.24. Reported GAAP earnings are close to meaningless right now because of formation gains and IPO costs, and on a pro forma basis the company showed a net loss of about ~$48.6M for the first half. What an investor is really pricing is a small, externally managed, equity-funded roll-up of an asset class with a demographic tailwind, at a forward FFO multiple in the low thirties and a dividend yield under ~2%.

Healthpeak controls about ~69.7% of the voting power and also supplies the external manager, whose fee is tied to the gross book value of investments acquired, which rewards balance sheet growth whether or not it earns its cost of capital. Operator concentration is heavy: LCS accounted for roughly ~66% of gross real estate assets and about ~65% of second quarter revenue, so the quality of one privately held partner matters enormously. Geographic concentration compounds it, with Florida at roughly ~51% of gross real estate assets and a casualty history that includes hurricane charges. The entrance fee model carries ~$699M of deferred revenue and ~$227M of refundable obligations that depend on units being resold on schedule, and slow re-occupancy turns that liability into a working capital drain. Two follow-on offerings inside five months show how the growth is being paid for, and a company that is guiding to ~$0.95 to ~$0.98 of FFO as Adjusted per share while trading near ~$30 has priced in a lot of successful future deployment.

12 analysts publish price targets on JAN, averaging $32.08 against a $30.63 price as of August 2026, or +4.7%. The published targets run from $28.00 to $40.00, a moderate spread, and the ratings split 11 buy, 1 hold, 0 sell. Over the last six months there have been 9 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full JAN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Janus Living, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Occupancy and rate, with almost no new supply arriving. Senior housing construction starts collapsed after 2020 and have stayed low, while the population turning 80 is rising sharply. The most optimistic published target, $40.00, assumes this works close to its best case.

The case against. Healthpeak controls about ~69.7% of the voting power and also supplies the external manager, whose fee is tied to the gross book value of investments acquired, which rewards balance sheet growth whether or not it earns its cost of capital. The most pessimistic target, $28.00, is roughly what JAN is worth if this bites instead.

Read the full bull and bear case on JAN, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Janus Living, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$723M
• Q2 2026 revenue: ~$216M, up ~45% year over year
• FFO as Adjusted (Q2 2026): ~$0.24 per share, up ~40%
• 2026 guidance, FFO as Adjusted: ~$0.95 to ~$0.98 per share
• Cash and debt: ~$558M cash and no debt at August 3, before ~$447M of August offering proceeds
• Equity value: ~$7.0B of listed Class A-1 stock, or ~$9.3B including Healthpeak's operating company units

The reported price to earnings ratio for JAN runs into the hundreds and should be ignored, because first half GAAP income was dominated by a ~$46.3M gain on taking control of a joint venture and offset by ~$22.8M of IPO and transaction costs. FFO as Adjusted is the measure the company guides on, and at roughly ~$30 per share against guidance of ~$0.95 to ~$0.98 the stock changes hands near ~31 times, a premium to most diversified healthcare REITs. The ~$0.57 annualized dividend works out to a yield under ~2%, low for a REIT and a sign that the market is paying for growth here rather than income.

Other names that sit close to JAN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get JAN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so JAN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where JAN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

JAN is the cleanest listed way to own senior housing operating income, sold at a multiple that assumes the occupancy and rate trend of the past two years keeps running.

Whether JAN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is JAN a buy or a sell?, and where the stock could go from here in the JAN stock forecast.

For income investors, whether JAN pays a dividend and how the payout looks is covered in does JAN pay a dividend? And to weigh JAN against a peer, read the full side-by-side comparisons: JAN vs WELL and JAN vs VTR.